Abstract
This review focuses on the mechanisms of action and the injurious effect of complex I inhibitors, of which 1-methyl-4-phenylpyridinium ion (MPP+) is a well studied example. These compounds can be divided into two groups, i.e. competitive inhibitors with respect to ubiquinone, such as piericidine A, and noncompetitive inhibitors such as rotenone. Complex I inhibitors such as MPP+ have been reported to induce anatomical, behavioral, and biochemical changes similar to those seen in Parkinsons disease, which is characterized by nigrostriatal dopaminergic neuro-degeneration. Spectroscopic analyses and structure-activity relationship studies have indicated that the V-shaped structure of the rotenone molecule is critical for binding to the rotenone binding site on complex I. Many isoquinoline derivatives, some of them endogenous, are also complex I inhibitors. Many lines of evidence show that complex I inhibitors elicit neuronal cell death. Recently, it was reported that chronic and systemic exposure to low-dose rotenone reproduces the features of Parkinsons disease. This work further focused attention on compounds acting on mitochondria, such as MPP+. In Guadeloupe, the French West Indies, patients with atypical parkinsonism or progressive supranuclear palsy are frequently encountered. These diseases seem to be associated with ingestion of tropical herbal teas or tropical fruits of the Annonaceae family, which contain complex I inhibitors such as benzylisoquinoline derivatives and acetogenins. Complex I inhibitors may not simply result in reactive oxygen species generation or ATP exhaustion, but may influence complex downstream signal transduction processes. An understanding of these changes would throw light on the ways in which complex I inhibitors induce a wide range of abnormalities.
Keywords: complex I inhibitor, parkinson's disease, rotenone, apoptosis, tetrahydroisoquinoline, benzylisoquinoline alkaloid, acetogenin
Current Medicinal Chemistry
Title: MPP+ Analogs Acting on Mitochondria and Inducing Neuro-Degeneration
Volume: 10 Issue: 23
Author(s): Y. Kotake and S. Ohta
Affiliation:
Keywords: complex I inhibitor, parkinson's disease, rotenone, apoptosis, tetrahydroisoquinoline, benzylisoquinoline alkaloid, acetogenin
Abstract: This review focuses on the mechanisms of action and the injurious effect of complex I inhibitors, of which 1-methyl-4-phenylpyridinium ion (MPP+) is a well studied example. These compounds can be divided into two groups, i.e. competitive inhibitors with respect to ubiquinone, such as piericidine A, and noncompetitive inhibitors such as rotenone. Complex I inhibitors such as MPP+ have been reported to induce anatomical, behavioral, and biochemical changes similar to those seen in Parkinsons disease, which is characterized by nigrostriatal dopaminergic neuro-degeneration. Spectroscopic analyses and structure-activity relationship studies have indicated that the V-shaped structure of the rotenone molecule is critical for binding to the rotenone binding site on complex I. Many isoquinoline derivatives, some of them endogenous, are also complex I inhibitors. Many lines of evidence show that complex I inhibitors elicit neuronal cell death. Recently, it was reported that chronic and systemic exposure to low-dose rotenone reproduces the features of Parkinsons disease. This work further focused attention on compounds acting on mitochondria, such as MPP+. In Guadeloupe, the French West Indies, patients with atypical parkinsonism or progressive supranuclear palsy are frequently encountered. These diseases seem to be associated with ingestion of tropical herbal teas or tropical fruits of the Annonaceae family, which contain complex I inhibitors such as benzylisoquinoline derivatives and acetogenins. Complex I inhibitors may not simply result in reactive oxygen species generation or ATP exhaustion, but may influence complex downstream signal transduction processes. An understanding of these changes would throw light on the ways in which complex I inhibitors induce a wide range of abnormalities.
Export Options
About this article
Cite this article as:
Kotake Y. and Ohta S., MPP+ Analogs Acting on Mitochondria and Inducing Neuro-Degeneration, Current Medicinal Chemistry 2003; 10 (23) . https://dx.doi.org/10.2174/0929867033456558
DOI https://dx.doi.org/10.2174/0929867033456558 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano Strategies for Diagnosis and Treatment of Inflammatory Hyperalgesia
Current Nanomaterials Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Possible Involvement of Programmed Cell Death Pathways in the Neuroprotective Action of Polyphenols
Current Alzheimer Research Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research The IFN-λ Family (IL-28/29)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds
Letters in Drug Design & Discovery Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Antifreeze Proteins from Diverse Organisms and their Applications: An Overview
Current Protein & Peptide Science C-type Lectin-related Proteins from Snake Venoms
Current Drug Targets - Cardiovascular & Hematological Disorders What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Cell Therapy Using Induced Pluripotent Stem Cells or Somatic Stem Cells: This is the Question
Current Stem Cell Research & Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Smart Drug Release Systems Based on Stimuli-Responsive Polymers
Mini-Reviews in Medicinal Chemistry Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Current Drug Targets Tuftsin – Properties and Analogs
Current Medicinal Chemistry